T he hematologic manifestations of acquired copper deficiency are well known and include anemia, neutropenia, and a left shift in granulocytic and erythroid maturation with vacuolated precursors and ringed sideroblasts in the bone marrow. [1] [2] [3] [4] Only in recent years have the neurological manifestations of acquired copper deficiency in humans been recognized. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The most common manifestation is that of a myelopathy presenting with a spastic gait and prominent sensory ataxia. 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] 23 Clinical or electrophysiological evidence of an associated peripheral neuropathy is common. Isolated peripheral neuropathy, 4,7 central nervous system (CNS) demyelination, 5, 8 myopathy, 14 and optic neuritis 7 have also been described in association with copper deficiency, but these associations are less well established. Often, the cause of the copper deficiency is unclear. The most common abnormality on the spinal magnetic resonance image (MRI) is increased signal on T2-weighted images that involve the dorsal column in the cervical cord. 20 Somatosensory evoked potential and nerve conduction studies suggest impaired central conduction and varying degrees of peripheral neuropathy. 22 Response of the anemia and neutropenia to copper supplementation is prompt and complete. 4, 7, 12, 15 With copper supplementation, the neurological deterioration may be prevented, and improvement is slight and often subjective. 4, 8, 12, 15 In this article, I describe patients with copper deficiency myelopathy and review the literature on neurological manifestations of acquired copper deficiency in humans.
PATIENTS AND METHODS
The case records of 25 patients with copper deficiency myelopathy seen at the Mayo Clinic in Rochester, Minn, were reviewed. These 25 patients include 13 patients described earlier as a series. 15 Our experience with the 25 patients described herein has been previously published in abstract form 18, 22 ; details regarding the neuroimaging findings in this cohort have been previously published, 20 as have the clinical details of some cases. 9, 11, 13, 14, 16, 21 All 25 patients were evaluated as part of routine clinical practice within the Department of Neurology. Only 2 patients (patients 13 and 14) were identified retrospectively. Of the 25 patients, 23 were evaluated within a 24-month period. Demographic information, clinical presentation, laboratory and neurophysiological findings, neuroimaging, and response to therapy were studied. Additional investigations were performed in each patient to rule out other causes of a noncompressive myelopathy. Wilson disease as a cause of low serum copper levels was excluded in all patients by 24-hour urinary copper excretion and/or slit lamp examination for Kayser-Fleischer rings.
Available MRI studies were reviewed by a neuroradiologist. Cervical and thoracic spine MRIs were available in all patients except patient 13, in whom only a cervical spine MRI was available. Contrast imaging was performed in 14 of the 25 patients (patients 4-10, 16-19, 21, 22, and 24) . A brain MRI was available in all except patients 4, 11, 20, and 25. The images were acquired using a 1.5-T strength magnet.
Electrophysiological tests included nerve conduction studies, needle electromyography, and somatosensory and visual evoked potentials. The electrophysiological studies were performed using standard techniques for our laboratory. Nerve conduction studies were available in all pa-tients except patient 16 . Somatosensory evoked potential studies were available in 20 patients (all except patients 3, 10, 14, 16, and 19). Of these 20, both tibial and median somatosensory evoked potential studies were performed in 17, tibial only in 1 (patient 11), and median only in 2 (patients 13 and 21). Eight patients had visual evoked potential studies performed (patients 6, 16, 17, 18, 19, 21, 22, and 24) . In 1 patient (patient 16), it was the only electrophysiological testing done.
In 2 patients with hypocupremic myelopathy and no evident cause of copper deficiency, colonic copper was measured to determine whether an absorptive defect similar to that seen in Menkes syndrome may have been responsible for the hypocupremia (patients 17 and 23). In 1 of these 2 patients (patient 17), mutations in the ATP7A gene were sought to determine whether a mutation similar to that seen in Menkes syndrome could have been responsible for the hypocupremia and increased colonic mucosal copper content.
RESULTS

DEMOGRAPHICS AND CLINICAL FEATURES
The demographics of this cohort, duration of neurological symptoms before diagnosis, and likely cause of copper deficiency are summarized in Table 1 . Also shown in Table 1 and Figure 1 are serum copper and zinc levels at presentation. The duration of neurological symptoms before the diagnosis of copper deficiency myelopathy ranged from 2 months to 10 years. The age range at the time of diagnosis was 36 to 78 years (mean age, 56 years). Twenty of the 25 patients were women. The serum copper level ranged from being undetectable in 8 to 0.45 µg/mL in 1 (reference range, 0.75-1.45 µg/mL). The mean serum copper level at presentation in this cohort was 0.13 µg/mL. A high or high-normal serum zinc level was seen in 17 of the 23 patients for whom this information was available.
The presenting complaint was gait difficulty, and all patients reported lower limb paresthesias. The gait difficulty was primarily due to severe sensory ataxia secondary to dorsal column dysfunction. In some patients, the gait also had a mild spastic component with associated corticospinal signs. Symptoms suggestive of an upper motor neuron bladder were present in 9 patients, a Lhermitte sign was present in 3 patients, and upper limb signs or symptoms were present in all except 2 patients (Table 2) . A brisk knee jerk was seen in all except 4 patients. The ankle jerk was depressed in 15 patients, and an extensor plantar response was seen in 12 patients.
POSSIBLE CAUSE OF HYPOCUPREMIA
In one patient, copper deficiency was secondary to consumption of excessive amounts of zinc (patient 1) and in another possibly due to large doses of iron (patient 2). In 10 patients, the hypocupremia was attributed to a history of gastric surgery (patients 3-12), and in 4 it was due to malabsorption (patients [13] [14] [15] [16] . In the remaining 9 patients, the origin of the hypocupremia was unclear. The colonic copper level in patients 17 and 23 was increased to 39 µg/g and 57 µg/g of dry weight, respectively (reference range, 6-13 µg/g of dry weight). DNA sequence analysis of the ATP7A gene in patient 17 did not demonstrate any abnormalities. 24 All 22 coding exons and flanking introns were sequenced.
LABORATORY INVESTIGATIONS
Anemia or leukopenia at presentation or in the past was seen in all except 5 patients (patients 1, 5, 15, 21, and 24) ( Table 2) . A history of vitamin B 12 deficiency was present in 9 patients. Of these, 7 had a prior history of gastric surgery. All patients had a normal vitamin B 12 level at presentation. The methylmalonic acid level was available in 14 patients (patients 2-7, 10, 12, 14, 16-19, and 21) and was elevated in 3 (patients 6, 10, and 21). Serum homocysteine measurements were within the reference range in the 14 patients for whom this information was available (patients 3-7, 12, 14, 16-19, 21, 23, and 24) . Patients with a history of vitamin B 12 deficiency showed neurological progression despite periodic vitamin B 12 administration and repeatedly normal vitamin B 12 levels.
ELECTROPHYSIOLOGICAL STUDIES
Clinical findings and nerve conduction studies suggested varying degrees of peripheral neuropathy (Table 3 ). An axonal peripheral neuropathy was detected in 21 of 24 patients. Eleven were mixed sensory motor, 5 were pure motor, 2 pure sensory, 2 predominantly motor, and 1 predominantly sensory. The neuropathy was mild in 10, moderately severe in 3, and severe in 8. In 3 patients, severe, bilateral, posterior interosseous neuropathies were superimposed on the generalized neuropathy. Myopathic changes were noted on the electromyogram in 4 patients (patients 6, 13, 23, and 24). Somatosensory evoked potential studies were abnormal in all 20 patients in whom these data were available, although in patient 13 the abnormality was only peripheral. Nineteen patients had neurophysiological evidence of impaired conduction in the central pathways. This correlated with the clinical presentation that suggested myelopathy. Visual evoked poten- Table 3 ). The cervical cord was involved in 10 (patients 3-9, 17, 22, and 24), thoracic cord in 6 (patients 4-8 and 21), and both in 5 (patients 4-8). Of the 6 patients with thoracic cord involvement, the involvement was contiguous with the cervical involvement in 2 (patients 5 and 6).
The involvement was most often in the paramedian dorsal cord that involved the dorsal columns ( Figure 2 , A and B), although in 2 patients (patients 9 and 21) the central cord was involved. It is difficult to be certain that this did not represent a small central syrinx. Slight cord atrophy of the thoracolumbar cord was seen in 3 patients (patients 3, 21, and 24). Of the 11 patients with signal change in the spinal cord, contrast was given in all except 1 (patient 3). None of these 10 had any evidence of contrast enhancement. Often the involvement was subtle and in 2 patients (patients 3 and 24) had been missed before a neuroradiologist's review. Foci of increased T2 signal on the brain MRI were seen in 15 patients (patients 1, 3, 5-7, 9, 10, 15, 16, 18, 19, 21, and 22-24), and in some (patients 1, 6, 7, 19, 22, and 24) the appearance and distribution of the lesions suggested lacunar disease. The importance of this finding is uncertain.
RESPONSE TO THERAPY AND FOLLOW-UP
Inadequate follow-up data were available for patients 7, 9, 12, 16, and 25. With oral or parenteral copper replacement, normal serum copper levels were achieved in 18 of the remaining 20 patients (Table 4 ). Hematologic manifestations when present were promptly and completely reversed. Residual neurological deficits were present in all 20. In all 20 patients except patient 5, further deterioration was prevented. A few months after diagnosis, patient 21 died after a massive stroke. Neurological improvement when present was often more subjective than objective. The cervical dorsal column signal change noted on the T2- weighted MRI in patient 17 showed nearly complete resolution with normalization of serum copper.
DISCUSSION NEUROLOGICAL MANIFESTATIONS IN COPPER-DEFICIENT ANIMALS
Copper deficiency-associated myelopathy has been well described in various animal species. [25] [26] [27] [28] [29] Often seen in ruminants, it has been referred to as swayback or enzootic ataxia. The typical distribution of lesions in the spinal cord is greater involvement of the cervical cord with less severe changes in the thoracic and lumbar segments.
29 Wallerian degeneration and demyelination with microcavitation of the white matter of the spinal cord and brainstem are seen. 26 Menkes syndrome is the well-known copper deficiencyrelated disease in humans and is due to congenital copper deficiency. 30, 31 Comparative neuropathological studies have shown similarity between Menkes syndrome and swayback. 28 Both are characterized by defects in mitochondrial oxidative metabolism due to a decrease in a copper metalloenzyme, cytochrome oxidase. 32, 33 Abnormalities of CNS myelination are seen in copper-deficient rats.
34,35
Zinc-induced copper deficiency has been known to cause ataxia in kittens who were exposed to zinc from the galvanized iron bar doors of their cages. 36 Wallerian degeneration in the spinal cord was present at necropsy.
ROLE OF COPPER IN MAINTAINING THE STRUCTURE AND FUNCTION OF THE NERVOUS SYSTEM
Copper functions as a prosthetic group, permitting electron transfer in key enzymatic pathways. It is a component of key metalloenzymes that have a critical role in the structure and function of the nervous system. These include cytochrome-c oxidase for electron transport and oxidative phosphorylation in the mitochondrial respiratory chain, copper-zinc superoxide dismutase for antioxidant defense, tyrosinase for melanin synthesis, dopamine β-hydroxylase for catecholamine biosynthesis, lysyl oxidase for crosslinking of collagen and elastin, peptidylglycine α-amidating monooxygenase for neuropeptide and peptide hormone processing, and ceruloplasmin for brain iron homeostasis. Reduction in cytochrome oxidase activity may be the likely basis for neurological dysfunction associated with the copper deficient state.
CAUSES OF COPPER DEFICIENCY
In the study patients, the most common association with copper deficiency was a remote history of gastric surgery. 
COPPER DEFICIENCY MYELOPATHY
Copper absorption in humans most likely occurs in the stomach and proximal duodenum. 37 Prompt appearance of copper 64 in the blood after oral administration suggests that most copper absorption occurs from the proximal gut. 38 Although no data are available on the incidence or prevalence of hypocupremia after gastric surgery, copper deficiency after gastric surgery (for peptic ulcer disease or bariatric surgery) is being increasingly recognized. 6, 7, 11, 13, 15, 16, 18, 23, 39 Neurological complications after gastrectomy for ulcer disease or bariatric surgery have been well recognized, but frequently the cause has not been determined. [40] [41] [42] [43] [44] [45] [46] Excessive zinc ingestion, although seen in only 1 of the study patients (patient 1), is a well-recognized cause of copper deficiency (Figure 3, A) . [2] [3] [4] 9, 19, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] In addition to the common use of zinc in the prevention or treatment of common colds and sinusitis, zinc therapy has been used for conditions such as acrodermatitis enteropathica, decubitus ulcers, sickle cell disease, celiac disease, memory impairment, and acne. Unusual sources of excess zinc have included a patient who consumed an entire tube of a denture cream that contained zinc daily for 5 years 4 and patients swallowing coins containing zinc. 53, [55] [56] [57] Zinc causes an upregulation of metallothionein production in the enterocytes. 59 Metallothionein is an intracellular ligand, and copper has a higher affinity for metallothionein than zinc. Copper displaces zinc from metallothionein, binds preferentially to the metallothionein, remains in the enterocytes, and is lost in the feces as the intestinal cells are sloughed off (Figure 3, A) . In patient 2, excess iron consumption may have contributed to the hypocupremia. In animals, excess iron has been associated with copper deficiency. [60] [61] [62] If the diagnosis of copper deficiency is not suspected, iron supplementation may be administered for presumed iron deficiency anemia, which may further exacerbate the copper deficiency. 13, 63, 64 The extent to which oral iron interferes with copper absorption in humans is unknown. Tetrathiomolybdate may have a role in inhibiting tumor angiogenesis, and chemotherapy regimens using tetrathiomolybdate can also result in copper deficiency. 65, 66 Copper deficiency since birth is seen in Menkes syndrome. 30 In this syndrome, copper absorption from the gut is impaired, 31 and high levels of copper are seen in duodenal mucosal cells. 67 A defect in enterocyte transport of *Hematologic manifestations when present showed a prompt and complete response to therapy. Neurological improvement when present was often more subjective than objective. IV = intravenous; PO = oral; ? = inadequate follow-up data.
absorbed copper causes copper accumulation in the intestinal mucosa and resulting hypocupremia (Figure 3, A) . The genetic basis is mutations in the ATP7A gene, which encodes a P-type adenosine triphosphatase (MNK) that has multiple copper binding motifs near its amino terminus. [68] [69] [70] Loss of function of this protein results in failure of copper transfer across the gastrointestinal tract, placenta, and blood-brain barrier, with resultant copper deficiency. The increased colonic copper seen in patients 17 and 23 suggests that a similar defect in copper transport may underlie idiopathic hypocupremia. Similar observations have been made in a patient with a progressive neurological disease and hypocupremia. 71 Even though an ATP7A mutation was not identified in patient 17, changes in the promoter or other noncoding regions and large intragenic deletions could not be ruled out.
It is known that mutations in the ATP7A gene are responsible for a wide spectrum of manifestations of Menkes syndrome. 72 Emerging knowledge about copper transport 73, 74 may help clarify the origin of idiopathic hypocupremia. Studies in yeast have shown that reduced copper is transported across the membrane by the high-affinity copper transporter Ctr1, and 3 different proteins transport copper to cytochrome-c oxidase, copper-zinc superoxide dismutase, and the post-Golgi compartment for insertion into a multicopper oxidase essential for high-affinity iron uptake ( Figure  3, B) . The copper transporter Ctr1 is the primary avenue for copper uptake in mammalian cells and provides an essential function in mammalian embryonic development. 75 Copper deficiency may occur in premature infants and low-birth-weight infants.
76, 77 Because of copper's ubiquitous distribution and low daily requirement, acquired dietary copper deficiency is rare. 78 It may occur in malnourished infants, 63, [79] [80] [81] patients with nephrotic syndrome, 82 and those with enteropathies associated with malabsorption. 14, [83] [84] [85] [86] Malabsorption without a history of gastric surgery was the second most commonly identified cause of hypocupremia in the cohort.
Copper deficiency may be a complication of prolonged total parenteral nutrition, 64, [87] [88] [89] [90] [91] [92] particularly so when copper supplementation in total parenteral nutrition is withheld because of cholestasis. 93, 94 Enteral feeding with inadequate copper has also been known to result in copper deficiency. 95, 96 ASSOCIATED HYPERZINCEMIA An elevated serum zinc level in the absence of exogenous zinc ingestion was commonly seen in the study patients. Hyperzincemia in association with hypocupremia has also 
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been reported by others. 4, 8, 10, 12 The hyperzincemia (as assessed by increased serum zinc or urinary zinc excretion) may persist or increase despite correction of the copper deficient state. 8, 10, 12, 15 The importance of the associated hyperzincemia seen in the absence of exogenous zinc ingestion is unclear, 97, 98 as is the importance of increased urinary zinc excretion without elevation of the plasma zinc level. 11, 14 Copper deficiency may result from a zinc overload syndrome. 10 A metabolic abnormality that results in increased zinc absorption or decreased intestinal excretion has been proposed. Since the syndrome of myeloneuropathy has been described with hypocupremia and normal zinc levels, 6, 11, [13] [14] [15] 18 it is unlikely that hyperzincemia is causative. No definite reports have been published of neurological toxicity due to hyperzincemia without hypocupremia in animals or humans. Elevated zinc levels have been described as a heritable anomaly with no clinical manifestations. 99 High doses of oral zinc have been administered long term in patients with Wilson disease with no development of neurological complications. The hyperzincemia seen in some patients with neurological manifestations and copper deficiency is probably a secondary feature associated with the hypocupremia.
ASSOCIATED VITAMIN B 12 DEFICIENCY
Some of the study patients had a history of vitamin B 12 deficiency, most of whom had undergone gastric surgery. None of the patients had low vitamin B 12 levels at the time the copper deficient state was diagnosed. The myelopathy of copper deficiency closely mimics the subacute combined degeneration of vitamin B 12 deficiency. 15 Copper and vitamin B 12 deficiency may coexist. 4, 15 Patients may be given vitamin B 12 despite normal serum vitamin B 12 levels. 6 A similar spine MRI appearance can be seen in patients with vitamin B 12 deficiency. 100 
CLINICAL FEATURES, NEUROPHYSIOLOGY, AND NEUROIMAGING IN COPPER DEFICIENCY MYELOPATHY
The clinical presentation of all the study patients was that of a gait difficulty primarily due to severe sensory ataxia. The sensory ataxia was primarily due to dorsal column dysfunction. At times, symptom onset was subacute. Clinical or electrophysiological evidence of a peripheral neuropathy was often present. Involvement of the peripheral nervous system was not the predominant reason for the sensory ataxia in any patient. The MRI and evoked potential studies provided additional evidence of posterior column dysfunction (Table 3 , Figure 2, A and B) . The most consistent finding on spine MRI is increased signal on T2-weighted images that involve the dorsal columns. The cervical cord is most commonly involved, and contrast enhancement is not present. Follow-up imaging was available in 1 patient (patient 17) and showed resolution of the dorsal column signal change with improvement in serum copper. 20 Vitamin B 12 deficiency and copper deficiency can coexist, and the ataxic myelopathy of copper deficiency can mimic the subacute combined degeneration seen with vitamin B 12 deficiency. 15 Clioquinol, a copper-zinc chelating antibiotic, is the likely etiologic agent in subacute myelo-opticoneuropathy, 101 and both copper deficiency myelopathy and myelo-opticoneuropathy are characterized by involvement of the dorsal column and corticospinal tracts. It is speculative whether copper deficiency could have been the proximate cause of myelo-opticoneuropathy. 102 Table 5 details the salient features in some of the other described patients with neurological manifestations due to acquired copper deficiency.
Most of the noted areas of increased T2 signal on brain MRI in the study patients were nonspecific; however, the appearance and distribution of some of these lesions suggested lacunar disease. Neuropathological studies in Menkes syndrome have shown arterial tortuosity and fragmentation of the internal elastica in large arteries.
31 Some of the pathological changes in the CNS in Menkes syndrome are likely due to vascular involvement. Experimental copper deficiency has been associated with aneurysmal dilation of large arteries and massive hemorrhage. 104 The possible role of acquired copper deficiency in cerebrovascular disease requires further study. Two described patients have had brain MRI findings that were believed to be consistent with demyelinating disease. 5, 8 The importance of the brain MRI findings requires further study. Neurophysiological studies show varying degrees of axonal peripheral neuropathy, at times predominantly motor. Abnormalities in somatosensory evoked potential studies indicating central conduction delay are common. Other reported electrophysiological abnormalities noted in patients with copper deficiency and neurological manifestations include prolonged visual evoked potentials 5 and impaired central conduction on transcranial magnetic stimulation. 6 ASSOCIATED HEMATOLOGIC MANIFESTATIONS A history of anemia or leukopenia or anemia or leukopenia at presentation was present in most of the study patients. It is being increasingly recognized that hematologic manifestations may not accompany the neurological syndrome. 9, 15, 18, 105 The hematologic hallmark of copper deficiency is anemia and neutropenia. 1, 51, 95, 96, 106 The anemia may be microcytic, 49,51,54 macrocytic, 4, 7 or normocytic. 4, 95 Thrombocytopenia and resulting pancytopenia are relatively rare. [92] [93] [94] A prolonged copper deficient state may be necessary for the development of thrombocytopenia. 1, 7 The bone marrow findings are not pathognomic but are highly characteristic, and reports have been published of patients in whom the diagnosis of the copper deficient state was first suggested by the bone marrow findings. 4 Patients may be diagnosed as having sideroblastic anemia or myelodysplastic syndrome. 3, 4, 7, 21, 50, 52, 57 In one described patient with copper deficiency and hematologic abnormalities, a pretransplantation evaluation was considered, and treatment with blood transfusions, erythropoietin, and granulocyte colony-stimulating factors was given before copper deficiency was detected. 7 Copper-containing enzymes likely play a role in cell differentiation and proliferation in the bone marrow. Impaired erythroid and myeloid maturation and reduced erythrocyte and neutrophil life spans are the likely reasons for the anemia and neutropenia.
TREATMENT OF COPPER DEFICIENCY
No studies have addressed the most appropriate dose, duration, route, and form of copper supplementation. Little information is available on human copper stores. Serum copper may be inadequate for assessing total body copper stores, and activity of copper enzymes, such as erythrocyte superoxide dismutase and platelet or leukocyte cytochrome-c oxidase, may be a better indicator of metabolically active copper stores. [107] [108] [109] In patients with zinc-induced copper deficiency, discontinuing use of the zinc may suffice, and no additional copper supplementation may be required. 4, 52, 54 At times, prolonged oral therapy may not result in improvement; parenteral therapy may be required, and elimination of excess zinc may be slow, and until such elimination occurs, the intestinal absorption of copper may be blocked. 51 Some investigators have used initial parenteral administration followed by oral administration. 7, 19 Despite a suspected absorption defect, oral copper supplementation is generally the preferred route of supplementation. Copper supplements may not be adequately absorbed when administered through a jejunostomy tube, necessitating parenteral therapy. 110 Studies of yeast have shown that the copper transport pathways are high-affinity pathways active in conditions of low copper concentration, and increasing the concentration of copper may result in the pathways being bypassed. 73 This may explain why in most of the current study patients normal serum copper levels were achieved by increasing the amount of copper ingested. Oral administration of 2 mg/d of elemental copper seems sufficient. A comparable dose of elemental copper may be given intravenously. Doses as high as 9 mg/d orally have been used. 7, 10, 23 Commonly used copper salts include copper gluconate 23 and copper chloride. 7 The oral bioavailability of copper gluconate may be limited. 111 Currently, my colleagues and I at the Mayo Clinic give 6 mg/d of elemental copper orally for a week, 4 mg/d for the second week, and 2 mg/d thereafter. Periodic assessment of serum copper is essential to determine adequacy of replacement and the most appropriate long-term administration strategy. Because of the need for long-term replacement, parenteral therapy is not preferred and is generally not required. If required, a daily dose of 2 mg of elemental copper may be administered intravenously for 5 days periodically thereafter.
Response of the hematologic parameters (including bone marrow findings) is prompt and often complete. 3, 4, 7, 12, 49, 92, 95, 106 Hematologic recovery may be accompanied by reticulocytosis. 12, 64, 95, 106 Transient improvement with hematopoietic growth factors may occur even if copper deficiency is the cause of the hematologic manifestations. 7, 21 Recovery of neurological signs and symptoms seen in association with copper deficiency varies. Improvement in neurological symptoms is variable, although progression is typically halted. 4, 8, 12, 15, 18 A relapse in the copper deficient state may not be necessarily accompanied by neurological deterioration.
8 Improvement when present is often subjective and preferentially involves sensory symptoms. 6, 8, 11 There are some reports of definite improvement in the neurological deficits, 5, 10, 19 nerve conduction studies, 19 evoked potential studies, 9 and MRI T2 cord signal change 20 with normalization of serum copper.
CONCLUSION
I believe that myelopathy due to acquired copper deficiency in adults is an underrecognized syndrome. Estimation of serum copper levels should be a part of the work-up in patients with myelopathy or myeloneuropathy, particularly in those with a high risk of developing copper deficiency. Hematologic manifestations such as anemia or neutropenia are often but not always present. The presence of unexplained cytopenia in association with neurological manifestations should prompt clinicians to look for copper deficiency. It is unclear which patients may develop copper deficiency after gastric surgery and if routine screening and supplementation should be considered as is commonly done in these patients for vitamin B 12 deficiency. Given the increasing rates of bariatric surgery, this is a particularly pertinent issue. The copper deficient state may not manifest for decades. The role of the commonly observed hyperzincemia in the absence of exogenous zinc ingestion is unclear. The association between copper deficiency and CNS demyelination, isolated peripheral neuropathy, and optic neuritis requires further study. Studies are needed to determine the best dose, route, and duration of copper therapy. Further understanding of copper transport and trafficking may provide insights into the cause of copper deficiency in those with idiopathic hypocupremia.
ADDENDUM
Three additional patients with copper deficiency myelopathy and prior gastric surgery were recently described. [112] [113] [114] Also noteworthy is a recent report of 3 patients who presented with asymmetric lower motor neuron weakness, minimal sensory manifestations, and electrodiagnostic evidence of diffuse denervation, 2 of whom had a history of gastrointestinal surgery. 
